Verastem Culture Company

Dr. Robert A. Weinberg, also known as Bob, PhD. Co-Founded Theracrine, Inc. in 2010. Dr. Weinberg is Co-Founder of Verastem, Inc. and serves as its Chair of Scientific Advisory Board and served as its Co-Chair of Scientific Advisory Board. He has been a Member of Scientific Advisory Board at Syros Pharmaceuticals, Inc since April 2013. He serves as a Member of the Scientific Advisory Board at Astex Pharmaceuticals, Inc. Dr. Weinberg serves as a Member of the Scientific Advisory Board of SuperGen Inc., Asterand Bioscience, Inc. and Arqule Inc. He has been a Member of the Scientific Advisory Board at Cornerstone Pharmaceuticals Inc. since October 2009. He serves as a Member of the Scientific Advisory Board at Minerva Biotechnologies Corporation. has been an American Cancer Society Research Professor at Whitehead and MIT since 1985. He is a Founding Member of Whitehead Institute for Biomedical Research and the Daniel K. Ludwig Professor for Cancer Research in the Department of Biology at MIT. He joined the MIT faculty as a professor of biology in 1982. He is world renown for his expertise and vision in the basic understanding of the mechanisms that underlie cancers. He serves as a First Director of the Ludwig Cancer Center at MIT. He served on scientific advisory boards for the Institute of Molecular Pathology in Vienna, Austria and the Massachusetts General Hospital in Boston. Dr. Weinberg is the Author or Editor of five books and more than 350 articles. He has published a textbook The Biology of Cancer. He is an elected Member of the U.S. National Academy of Sciences and the Institute of Medicine and is a Fellow of the American Academy of Arts and Sciences. Among his honors are the Discover Magazine 1982 Scientist of the Year, the National Academy of Sciences/U.S. Steel Foundation Award in Molecular Biology, the Sloan Prize of the General Motors Cancer Research Foundation, the Bristol-Myers Award for Distinguished Achievement in Cancer Research, the Landon Prize of the American Association for Cancer Research, the Gairdner Foundation International Award, the Keio Medical Foundation Prize, 1997 National Medal of Science and the Otto Warburg Medal in 2007. He published the landmark paper Mechanism of Activation of a Human Oncogene in the journal Nature. In 1999, he published Creation of Human Tumor Cells with Defined Genetic Elements also in Nature. He did Postdoctoral Research at the Weizmann Institute in Rehovoth, Israel and the Salk Institute in La Jolla, California, and then returned to MIT in 1972. He received a B.S. in 1964 and Ph.D. in 1969 in Biology from MIT.

Mr. Daniel W. Paterson, also known as Dan, has been the Chief Operating Officer of Verastem, Inc. since December 12, 2014. Mr. Paterson served as Chief Business Officer of Verastem, Inc. from July 2013 to December 12, 2014. Mr. Paterson served as the Vice President and Head of Corporate Development and Diagnostics at Verastem, Inc. from March 2012 to July, 2013. Mr. Paterson served as the Chief Operating Officer of On-Q-ity Inc. Mr. Paterson served as the Chief Executive Officer and President of On-Q-ity Inc. (formerly, DNA Repair Company). Mr. Paterson's background includes more than twenty-five years in the healthcare industry, with extensive experience in oncology and almost 20 years managing venture-backed healthcare companies. He served as the Head of Global Strategy of Specialty Market and Patient-level Data at IMS Health. He joined IMS following the acquisition of PharMetrics where he served as a Vice President of Marketing and Corporate Development and also served as PharMetrics??? Vice President of Sales, Marketing and Business Development. He was responsible for developing strategy, product portfolio and key partnerships, resulting in the sale to IMS Health. He served as a Vice President of Product Management and Vice President of Business Development at CareTools, an innovative healthcare information systems company, where he had primary responsibility for management of the product portfolio and partnership strategy. Prior to CareTools he served as a Member of the founding management team of OnCare. Mr. Paterson began his career designing and managing clinical-trials programs in both industry and academic settings, including management of a nation-wide oncology clinical trials consortium headquartered at the Dana Farber Cancer Institute. He served as a Director of On-Q-ity Inc. Mr. Paterson serves as a Member of Advisory Board of Vitality, Inc. Mr. Paterson holds a B.S. in Biology from Boston University and attended Northeastern University Graduate Pharmacology Program.

Dr. Gregory I. Berk, also known as Greg, M.D. has been Senior Advisor at Verastem, Inc since January 19, 2017. Dr. Berk served as Chief Medical Officer at Verastem, Inc since April 15, 2016 until January 19, 2017. Dr. Berk served as President and Chief Medical Officer at Sideris Pharmaceuticals, Inc. since January 7, 2014 until December 2015. Dr. Berk served as Chief Medical Officer of DNIB Unwind, Inc. from December 2012 to January 14, 2014, where he led the clinical development of its oncology focused programs, including Phase 2 programs for both non-small cell lung cancer and metastatic castrate-resistant prostate cancer. Dr. Berk was responsible for leading the global clinical development strategy and clinical operations at BIND Therapeutics, Inc. He was employed at SuperGen. He served as Chief Medical Officer of Intellikine LLC since July 12, 2011. Dr. Berk served as Senior Vice President of Global Clinical Development at Celgene Corporation, where he was a key member of the Celgene-Abraxis Integration team during Celgene's acquisition of Abraxis BioScience. Prior to Celgene, Dr. Berk served as Senior Vice President of Global Clinical Development at Abraxis BioScience, where he was responsible for overall clinical strategy, including efforts to expand the indications for Abraxane in lung cancer, pancreatic cancer and malignant melanoma. During this time, Dr. Berk served as an investigator on several industry-sponsored and cooperative group clinical trials, including the pivotal trials for Gleevec(R) and Avastin(R). Dr. Berk has been Member of Clinical and Scientific Advisory Board at Verastem, Inc since January 19, 2017. Dr. Berk serves as a Member of Scientific Advisory Board at Cristal Therapeutics BV. Dr. Berk obtained his medical degree from Case Western Reserve University and completed his internship, residency and fellowship in internal medicine, hematology and medical oncology, at the Weill Medical College of Cornell University and New York Presbyterian Hospital, where he also served as a faculty member from 1989 to 2004.

Mr. John B. Green, also known as Jack, C.P.A., has been Chief Financial Officer of Dicerna Pharmaceuticals, Inc. since April 18, 2016. Mr. Green served as the Chief Financial Officer of Verastem, Inc. since May, 2013 until April 15, 2016. He served as Interim Chief Financial Officer of Dicerna Pharmaceuticals, Inc. from January 1, 2016 to April 18, 2016. He served as Senior Vice President of Finance of Revo Biologics from May 2002 to June 15, 2010 and its Chief Financial Officer from December 1994 and Treasurer from August 1997 to June 15, 2010. He was a key member of the senior management team for On-Q-ity and oversaw the financial activities, planning, budgeting and management of commercial and banking relationships. He served as Principal Accounting Officer at rEVO Biologics until June 15, 2010 Mr. Green served as Vice President of GTC Biotherapeutics Inc. since 1994. He served as Vice President and Assistant Treasurer of TSI Corporation from December 1989 to 1994. Mr. Green has been Consultant of Verastem, Inc. since April 15, 2016. He is a Certified Public Accountant (CPA) with over 30 years of financial experience, including 20 within the biotechnology industry. Mr. Green received a Master's Degree in Business Administration from Boston University Graduate School of Management and a Bachelor's degree from the College of the Holy Cross.

Mr. Richard H. Aldrich, also known as Rich, MBA, is a Co-Founder and Partner at Longwood Founders Management, LLC. Mr. Aldrich is the Founder at Verastem, Inc. and has been its Consultant since September 16, 2014. He is an Advisor at Bio*One Capital. He is a Co-Founder and Advisor at Flex Pharma Inc. He co-founded Altus Biologics. He served as General Partner at RA Capital Management, L.L.C., which he co-founded in 2001. He co-founded PPD Dermatology, Inc. Mr. Aldrich co-founded and helped to build several successful biotech companies including Vertex Pharmaceuticals, Sirtris Pharmaceuticals, Inc. in 2004, Alnara Pharmaceuticals, Inc. in 2008, Axial Biotherapeutics, Altus Pharmaceuticals, Concert Pharmaceuticals in 2006, Magen BioSciences, Inc. and Flex Pharma, Inc. He served as a Managing Member of RA Capital Management, L.L.C. from 2004 to 2008. He served as Chief Operating Officer of Vertex Pharmaceuticals Incorporated. He served as the Chief Business Officer and Senior Vice President at Vertex Pharmaceuticals Incorporated from 1989 to 2001, where he built and managed all commercial, financial and operating functions, Previously, he served at Integrated Genetics, Biogen Corporation and Boston Consulting Group. He has been the Chairman of KalVista Pharmaceuticals Ltd. since November 22, 2016. He has been the Chairman and Independent Director of Concert Pharmaceuticals, Inc. since May 2006. He has been Lead Independent Director of OvaScience, Inc. since March 2016. He has been a Director of KalVista Pharmaceuticals, Inc. since July 22, 2015. He serves as a Director of Altus Biologics. He serves as a Director of Colorescience, Inc., Combinatorx, Ingenium Pharmaceuticals GmbH, Tempero Pharmaceuticals, Inc., Magen BioSciences, Inc., and the Greater Boston YMCA. He has been a Director of Mitobridge, Inc. since October 7, 2013. He has been a Director of OvaScience, Inc. since July 2011. He is a Director of Renovia, Inc. He is a Director at Flex Pharma and Axial Biotherapeutics. He has been the Chairman of Alnara Pharmaceuticals, Inc. since May 2006. He is a Director at Flex Pharma and Axial Biotherapeutics. He has been Board Observer of Bicycle Therapeutics Limited since June 5, 2017. He co-founded OvaScience, Inc. in April 2011 and served as its Chairman since March 2012 until January 6, 2016. He served as the Chairman of FlexPharma. He served as Vice Chairman and Director of Massachusetts Eye and Ear Infirmary Inc. until March 7 2016. He served as a Vice Chairman and Director of Massachusetts Eye and Ear Associates Inc. He served as the Chairman of Zalicus Inc., until November 2004. He served as the Chairman of RA Capital Management, LLC and a Co-Founding Member from 2008 to 2011. He served as the Lead Director of Verastem Inc and PPD Dermatology, Inc. Mr. Aldrich served as a Director of PTC Therapeutics, Inc., since March 7, 2013 until June 10, 2015. He served as a Director of Verastem Inc. since August 2010 until September 16, 2014. He served as a Director of Sirtris Pharmaceuticals, Inc. since 2004. He served as an Independent Director of Altus Pharmaceuticals Inc., from October 2001 to July 27, 2006. He served as a Director of Trine Pharmaceuticals Inc., from October 2001 to February 10, 2003. He served as an Independent Director of Zalicus Inc. from June 2003 to May 2007. Mr. Aldrich holds an M.B.A. degree from the Amos Tuck School in Dartmouth and a B.S. degree in Management from Boston College.

Eric Nichols serves as the VP Commercial Operations of Verastem. Eric started at Verastem in April of 2018. Eric currently resides in Greater Boston Area.

Robert Pintar serves as the Vice President, Technical Operations of Verastem. Robert started at Verastem in January of 2018. Robert currently resides in Greater Boston Area.

Stephen Jamieson serves as the VP Information Technology of Verastem. Stephen started at Verastem in January of 2018. Stephen currently resides in Greater Boston Area.